Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Company Information
About this company
Key people
Joseph Hazelton
President, Chief Operating Officer
Mark A. Emalfarb
Chief Executive Officer, Director
Ping Wang Rawson
Chief Financial Officer
Ronen Tchelet
Vice President - Research and Business Development
Patrick K. Lucy
Independent Chairman of the Board
Seth J. Herbst
Independent Director
Jack L. Kaye
Independent Director
Click to see more
Key facts
- Shares in issue48.44m
- EPICDYAI
- ISINUS26745T1016
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$31.81m
- Employees6
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.